论文部分内容阅读
目的:研究奥曲肽联合卡托普利治疗肝硬化难治性腹水的疗效。方法:59例肝硬化难治性腹水患者被随机分为两组,治疗组(29例)在常规治疗药物治疗上的加奥曲肽及卡托普利,对照组(30例)在常规治疗药物治疗上的加卡托普利,观察患者治疗后的腹围、血清尿素氮、肌酐和白蛋白、疗效。结果:治疗组总有效率82.7%(24/29)高于对照组60.%(18/30)(P<0.01),腹围低于对照组(P<0.05),治疗后两组血生化及肾功能指标间差异无统计学意义(P>0.05)。结论:奥曲肽联合卡托普利治疗肝硬化难治性腹水有较好的疗效和安全性。
Objective: To study the efficacy of octreotide combined with captopril in the treatment of refractory ascites due to cirrhosis. Methods: Fifty-nine patients with cirrhosis and refractory ascites were randomly divided into two groups. The treatment group (n = 29) received regular octreotide and captopril in the treatment group, and the control group (n = 30) On the captopril, observed after treatment of patients with abdominal circumference, serum urea nitrogen, creatinine and albumin, efficacy. Results: The total effective rate in the treatment group was 82.7% (24/29), which was significantly higher than that in the control group (60%, 18/30, P <0.01) and lower than that in the control group (P <0.05) There was no significant difference in renal function parameters (P> 0.05). Conclusion: Octreotide combined with captopril in the treatment of cirrhosis-refractory ascites have better curative effect and safety.